Hepatitis B vaccination status among patients with end-stage kidney disease on haemodialysis in Ethiopia: a multi-center cross-sectional study.

IF 2.2 4区 医学 Q2 UROLOGY & NEPHROLOGY
Rodas Temesgen Annose, Abdulsemed Mohammed Nur, Abel Zemenfes Tsige, Leja Hamza Juhar, Arsema Goytom Zegergsh
{"title":"Hepatitis B vaccination status among patients with end-stage kidney disease on haemodialysis in Ethiopia: a multi-center cross-sectional study.","authors":"Rodas Temesgen Annose, Abdulsemed Mohammed Nur, Abel Zemenfes Tsige, Leja Hamza Juhar, Arsema Goytom Zegergsh","doi":"10.1186/s12882-024-03703-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Chronic kidney disease patients, especially those on hemodialysis, are at increased risk of developing hepatitis B virus (HBV) infection. Guidelines suggest that all patients with chronic kidney disease patients should be vaccinated against HBV, but these guidelines are sub-optimally implemented. Notably, there is a lack of studies in Ethiopia examining the hepatitis B vaccination status among patients with end-stage renal disease.</p><p><strong>Objective: </strong>To assess the vaccination status of hepatitis B and associated factors among people with end-stage renal disease who were on hemodialysis.</p><p><strong>Methods: </strong>A multi-center cross-sectional observational study was conducted in six randomly selected dialysis centers in Ethiopia, from May 2023 to September 2023. Logistic regression analysis was used to evaluate factors associated with vaccination status. A person is considered to be vaccinated against hepatitis B if he/ she has taken at least one dose of HBV. Vaccination status was determined by patient's recall and verification from medical record.</p><p><strong>Results: </strong>Only 16% of patients with end-stage renal disease on hemodialysis were vaccinated against hepatitis B virus (16.6%; with CI = 12.18, 21.83), of which 30% had received one dose, 57.5% had two doses, 12.5% had three doses, and only five had a booster dose. Post-secondary education (AOR = 5.47; 95% CI = 1.41, 21.2; P < 0.014) and dialysis for more than three years (AOR = 19.75; 95% CI = 4.06, 96.1; P < 0.001) were significant factors associated with having received hepatitis B vaccination.</p><p><strong>Conclusion: </strong>Only a small minority of Ethiopian hemodialysis patients have received hepatitis B vaccination. The level of education of patients and the duration of time on dialysis were significant associated factors that affected the vaccination status of patients with end-stage renal disease. So, strong intervention is needed according to the identified factors to raise the vaccination status of patients.</p>","PeriodicalId":9089,"journal":{"name":"BMC Nephrology","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11373491/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12882-024-03703-x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Chronic kidney disease patients, especially those on hemodialysis, are at increased risk of developing hepatitis B virus (HBV) infection. Guidelines suggest that all patients with chronic kidney disease patients should be vaccinated against HBV, but these guidelines are sub-optimally implemented. Notably, there is a lack of studies in Ethiopia examining the hepatitis B vaccination status among patients with end-stage renal disease.

Objective: To assess the vaccination status of hepatitis B and associated factors among people with end-stage renal disease who were on hemodialysis.

Methods: A multi-center cross-sectional observational study was conducted in six randomly selected dialysis centers in Ethiopia, from May 2023 to September 2023. Logistic regression analysis was used to evaluate factors associated with vaccination status. A person is considered to be vaccinated against hepatitis B if he/ she has taken at least one dose of HBV. Vaccination status was determined by patient's recall and verification from medical record.

Results: Only 16% of patients with end-stage renal disease on hemodialysis were vaccinated against hepatitis B virus (16.6%; with CI = 12.18, 21.83), of which 30% had received one dose, 57.5% had two doses, 12.5% had three doses, and only five had a booster dose. Post-secondary education (AOR = 5.47; 95% CI = 1.41, 21.2; P < 0.014) and dialysis for more than three years (AOR = 19.75; 95% CI = 4.06, 96.1; P < 0.001) were significant factors associated with having received hepatitis B vaccination.

Conclusion: Only a small minority of Ethiopian hemodialysis patients have received hepatitis B vaccination. The level of education of patients and the duration of time on dialysis were significant associated factors that affected the vaccination status of patients with end-stage renal disease. So, strong intervention is needed according to the identified factors to raise the vaccination status of patients.

埃塞俄比亚血液透析终末期肾病患者的乙肝疫苗接种情况:一项多中心横断面研究。
背景:慢性肾病患者,尤其是血液透析患者,感染乙型肝炎病毒(HBV)的风险增加。指南建议所有慢性肾病患者都应接种乙型肝炎病毒疫苗,但这些指南的执行情况并不理想。值得注意的是,埃塞俄比亚缺乏对终末期肾病患者乙肝疫苗接种情况的研究:评估接受血液透析的终末期肾病患者的乙肝疫苗接种情况及相关因素:从 2023 年 5 月到 2023 年 9 月,在埃塞俄比亚随机抽取的 6 个透析中心开展了一项多中心横断面观察研究。采用逻辑回归分析评估与疫苗接种状况相关的因素。如果一个人至少接种过一剂乙肝疫苗,则被视为接种过乙肝疫苗。疫苗接种情况由患者回忆和病历核实确定:只有 16% 接受血液透析的终末期肾病患者接种了乙肝疫苗(16.6%;CI = 12.18,21.83),其中 30% 接种了一剂,57.5% 接种了两剂,12.5% 接种了三剂,只有 5 人接种了加强剂。大专以上学历(AOR = 5.47;95% CI = 1.41,21.2;P 结论:只有极少数埃塞俄比亚血癌患者接受过大专以上的教育:只有少数埃塞俄比亚血液透析患者接种过乙肝疫苗。患者的教育水平和透析时间是影响终末期肾病患者疫苗接种情况的重要相关因素。因此,需要根据已确定的因素采取强有力的干预措施,以提高患者的疫苗接种率。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMC Nephrology
BMC Nephrology UROLOGY & NEPHROLOGY-
CiteScore
4.30
自引率
0.00%
发文量
375
审稿时长
3-8 weeks
期刊介绍: BMC Nephrology is an open access journal publishing original peer-reviewed research articles in all aspects of the prevention, diagnosis and management of kidney and associated disorders, as well as related molecular genetics, pathophysiology, and epidemiology.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信